nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

01.11.2015 | Gynecologic Oncology

miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation

verfasst von: Delinaer Wuerkenbieke, Jing Wang, Yan Li, Cailing Ma

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Pertuzumab is a humanized mAb that binds to the extracellular region of HER2/ErbB2 and is approved for treating breast cancer. Although ovarian cancer and breast cancer have comparable levels of HER2/ErbB2 expression, clinical studies of pertuzumab in epithelial ovarian cancer patients have not met the same level of success.

Objectives

To investigate the molecular mechanisms by which pertuzumab exerts its anti-tumor effects in ovarian cancer and the mechanisms by which cancer cells achieve pertuzumab resistance.

Methods

We examined expression of miR-150 in ovarian cancer cells treated with pertuzumab or not. miR-150 knockdown impacts on pertuzumab treatment were analyzed by cell proliferation assay, apoptosis analysis and cell cycle analysis. Cell signal pathway was examined by western blot assay.

Results

Pertuzumab induced miRNA-150 expression in SKOV3 and SNU119 cells. Furthermore, suppression of miRNA-150 in both cell lines resulted in decreased drug sensitivity to pertuzumab and cell apoptosis. The blockage of G1/S checkpoint by pertuzumab was rescued as well. miRNA-150 knockdown activated PI3K-Akt pathway and LY294002 reversed the effect of miR-150 knockdown.

Conclusions

miRNA-150 downregulation may contribute to the pertuzumab resistance in ovarian cancer via, at least in part, PI3K-akt pathway.

Siegel RL, Miller KD (2015) Jemal A (2015) Cancer statistics. CA Cancer J Clin 65(1):5–29. doi:10.3322/caac.21254 CrossRefPubMed

Lengyel E (2010) Ovarian cancer development and metastasis. Am J Pathol 177(3):1053–1064. doi:10.2353/ajpath.2010.100105 CrossRefPubMedCentralPubMed

Yap TA, Carden CP, Kaye SB (2009) Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9(3):167–181. doi:10.1038/nrc2583 CrossRefPubMed

Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broet P, Guastalla JP, Allouache D, Combe M, Weber B, Pujade-Lauraine E, Camilleri-Broet S (2007) HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One 2(11):e1138. doi:10.1371/journal.pone.0001138 CrossRefPubMedCentralPubMed

Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9(7):463–475. doi:10.1038/nrc2656 CrossRefPubMed

Langdon SP, Faratian D, Nagumo Y, Mullen P, Harrison DJ (2010) Pertuzumab for the treatment of ovarian cancer. Exp Opin Biol Ther 10(7):1113–1120. doi:10.1517/14712598.2010.487062 CrossRef

Metzger-Filho O, Winer EP, Krop I (2013) Pertuzumab: optimizing HER2 blockade. Clin Cancer Res 19(20):5552–5556. doi:10.1158/1078-0432.ccr-13-0518 CrossRefPubMed

He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5(7):522–531. doi:10.1038/nrg1379 CrossRefPubMed

Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6(11):857–866. doi:10.1038/nrc1997 CrossRefPubMed

10.

He Y, Jiang X, Chen J (2014) The role of miR-150 in normal and malignant hematopoiesis. Oncogene 33(30):3887–3893. doi:10.1038/onc.2013.346 CrossRefPubMed

11.

Warth SC, Hoefig KP, Hiekel A, Schallenberg S, Jovanovic K, Klein L, Kretschmer K, Ansel KM, Heissmeyer V (2015) Induced miR-99a expression represses Mtor cooperatively with miR-150 to promote regulatory T-cell differentiation. EMBO J. doi:10.15252/embj.201489589 PubMed

12.

Jin M, Yang Z, Ye W, Xu H, Hua X (2014) MicroRNA-150 predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor ZEB1. PLoS One 9(8):e103965. doi:10.1371/journal.pone.0103965 CrossRefPubMedCentralPubMed

13.

Mraz M, Chen L, Rassenti LZ, Ghia EM, Li H, Jepsen K, Smith EN, Messer K, Frazer KA, Kipps TJ (2014) miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood 124(1):84–95. doi:10.1182/blood-2013-09-527234 CrossRefPubMedCentralPubMed

14.

Valabrega G, Montemurro F, Aglietta M (2007) Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18(6):977–984. doi:10.1093/annonc/mdl475 CrossRefPubMed

15.

Faratian D, Zweemer AJM, Nagumo Y, Sims AH, Muir M, Dodds M, Mullen P, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP (2011) Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. Clin Cancer Res 17(13):4451–4461. doi:10.1158/1078-0432.ccr-10-2461 CrossRefPubMed

16.

Nakajima H, Mizuta N, Sakaguchi K, Fujiwara I, Yoshimori A, Magae J, Tanuma S (2010) Enhancement of paclitaxel-induced apoptosis in HER2-overexpressing human breast cancer cells by a pertuzumab mimetic peptide,HRAP. J Biosci Bioeng 110(2):250–253. doi:10.1016/j.jbiosc.2010.02.007 CrossRefPubMed

17.

Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP (2009) Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res 15(12):4147–4156. doi:10.1158/1078-0432.ccr-08-2814 CrossRefPubMed

18.

Gajria D, Chandarlapaty S (2011) HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 11(2):263–275. doi:10.1586/era.10.226 CrossRefPubMedCentralPubMed

19.

Mullen P, Cameron DA, Hasmann M, Smyth JF, Langdon SP (2007) Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Mol Cancer Ther 6(1):93–100. doi:10.1158/1535-7163.mct-06-0401 CrossRefPubMed

20.

Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489–501. doi:10.1038/nrc839 CrossRefPubMed

21.

Greer EL, Brunet A (2005) FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24(50):7410–7425. doi:10.1038/sj.onc.1209086 CrossRefPubMed

22.

Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV (2010) FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res 70(13):5475–5485. doi:10.1158/0008-5472.can-10-0176 CrossRefPubMedCentralPubMed

23.

Nahta R, Esteva FJ (2006) Herceptin: mechanisms of action and resistance. Cancer Lett 232(2):123–138. doi:10.1016/j.canlet.2005.01.041 CrossRefPubMed

24.

Moasser MM (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26(45):6469–6487. doi:10.1038/sj.onc.1210477 CrossRefPubMedCentralPubMed

25.

Davis R, Singh KP, Kurzrock R, Shankar S (2009) Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors. Oncol Rep 22(6):1473–1478. doi:10.3892/or_00000589 PubMed

26.

Han J, Pan XY, Xu Y, Xiao Y, An Y, Tie L, Pan Y, Li XJ (2012) Curcumin induces autophagy to protect vascular endothelial cell survival from oxidative stress damage. Autophagy 8(5):812–825. doi:10.4161/auto.19471 CrossRefPubMed

27.

Zhou J, Liao W, Yang J, Ma K, Li X, Wang Y, Wang D, Wang L, Zhang Y, Yin Y, Zhao Y, Zhu WG (2012) FOXO3 induces FOXO1-dependent autophagy by activating the AKT1 signaling pathway. Autophagy 8(12):1712–1723. doi:10.4161/auto.21830 CrossRefPubMedCentralPubMed

28.

Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550–562. doi:10.1038/nrc2664 CrossRefPubMed

29.

Fruman DA, Rommel C (2014) PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discovery 13(2):140–156. doi:10.1038/nrd4204 CrossRefPubMed

Titel: miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation
verfasst von: Delinaer Wuerkenbieke
Jing Wang
Yan Li
Cailing Ma
Publikationsdatum: 01.11.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 5/2015
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-015-3742-x

Neu im Fachgebiet Gynäkologie und Geburtshilfe

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation

Abstract

Background

Objectives

Methods

Results

Conclusions

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie

Springer Medizin

Abstract

Background

Objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

Incidence of maternal and neonatal outcomes in pregnancies complicated by ovarian masses

The effects of progesterone in women undergoing preterm labor

Cesarean section and tissue adhesions

Humidification during laparoscopic surgery: overview of the clinical benefits of using humidified gas during laparoscopic surgery

Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up

Curettage or operative hysteroscopy in the treatment of cesarean scar pregnancy

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie